← All summaries
2026-11-05 · AI INVESTMENT RESEARCH

Policy tilt and order flow split on 4 November: US AI infrastructure sells off, China rallies

5 min readEnglish summaryFull briefing in Chinese →

On 4 November the same AI supply chain was discounted for policy in the US and given a policy premium in China. The briefing's view is that this was a beta rotation, not a change in alpha, because orders and earnings did not deteriorate. For the abundance thesis, nothing in the thesis changed. Positions moved on price discipline only, and the AMD, Coherent and Arm numbers all point the same way.

Key signals

  • US data-center names sold off on a Texas governor-elect's campaign pledge to pause data-center approvals (not law): Vertiv -12.9%, Eaton -9.9%, Micron -7.0%. The Philadelphia semiconductor index fell to its lowest since late April.
  • China: the central bank cut the buyback-lending rate to 1%. The STAR 50 rose 9.92%, the Hang Seng Biotech index 8.08%, and turnover returned to CNY 2.04 trillion, the first time above 2 trillion since 22 September.
  • Fundamentals held up. AMD guided Q4 revenue to $17.0bn (+66%) and above 80% for 2027. Coherent FQ1 revenue was $2.37bn (+50%), and Arm revenue rose 27%.
  • The tracking pool stopped out three names on intraday lows: MU (low 791.00 vs stop 813.40), ASML (1,478.96 vs 1,487.89) and COHR (187.16 vs 192.55). All three are in a cooling-off period until 18 November.
  • Missed rebound: names stopped out on 3 November (Zhongji Innolight, Cambricon, WuXi AppTec) rose about 10% or more on 4 November. The briefing records this as the cost of the discipline.

By theme

AI

  • AMD gave the cleanest demand read: Q3 revenue $13.4bn, data center $8.5bn (+97%). Shares closed +1.0% below the 50-day average after a high-volume day.
  • Arm FQ2 revenue was $1.443bn (+27%), but royalties of $670m missed the $721m expectation. Qualcomm's Q1 guide missed, with memory costs squeezing phone makers.
  • OpenAI agreed to buy Pierre Computer Company (terms undisclosed). Google guaranteed a roughly $19bn Anthropic data-park lease (amount marked as needing verification).
  • Cadence was the one chip-adjacent name to rise (+1.78%), closing back above its 200-day average.

Robotics

  • Intuitive Surgical rose 9.38% with no company announcement found (cause marked unverified). Its target-price upside is about zero.
  • Tesla fell 3.3% on political discount after the election, and Symbotic sits 0.02 above its 52-week low.
  • In Hong Kong, UBTech made a new intraday 52-week low of 60.20 before closing at 63.65.

Space

  • Small-cap space fell with the "Musk discount": Rocket Lab -3.8%, AST SpaceMobile -4.1% (new 52-week intraday low), Intuitive Machines -5.3%.
  • BlackSky reports before the open on 5 November, which is the first test of the watch pool's revenue-growth veto condition. Firefly reports 10 November, and Rocket Lab and AST SpaceMobile on 9 November.

Biotech

  • Regeneron hit a 52-week high of 991.73 intraday, then reversed to close -4.4% at 930.67. That leaves it 3.0% above its stop.
  • Beam's risto-cel update was accepted for an oral presentation at ASH in December. Beam stays on Sell (stopped out, cooling off until 16 November).
  • AI protein-design work (Pinal, RFD4-Proteina) points to design capacity outrunning wet-lab validation, which the briefing links to the CXO rally.

Hong Kong, A-shares and crypto

Hong Kong biotech and CXO surged (WuXi AppTec H +12.4%, BeiGene H +10.2%), and Hua Hong rose 15.8% the day before earnings. In A-shares, the three biggest compute gainers all opened high and closed lower, so limit-up moves did not show real follow-through. Bitcoin closed at 80,428, back above 80,000, but the briefing still waits for confirmation.

Rating highlights

TickerCompanyCallWhy
TSM:NYSETSMC ADRHold (downgraded)Closed below 200-day average 400.76; intraday low 0.6% from stop.
MU:NASDAQMicronSell (downgraded)Intraday low 791.00 hit stop 813.40; cooling-off until 18 November.
ASML:NASDAQASMLSell (downgraded)Intraday low 1,478.96 hit stop 1,487.89; cooling-off until 18 November.
COHR:NYSECoherentSell (downgraded)Stopped out intraday; strong after-hours earnings do not reverse exit.
CDNS:NASDAQCadenceBuyRose on a down day; closed above 200-day average.
VRT:NYSEVertivHoldEntered fallback range; selloff is policy expectation, not order data.
NVDA:NASDAQNvidiaSellStopped out 30 October; closed below 205.18 stop level again.
3692:HKEXHansoh PharmaHold (downgraded)Rose 6.83%; discipline bars a Buy on a day up 5% or more.
REGN:NASDAQRegeneronHoldReversed from 52-week high; 3.0% above stop.
2359:HKEXWuXi AppTec (H)SellCooling-off until 17 November; close 0.3% short of 50-day average.
688256:SSECambriconSellClose 847.66, 0.3% short of the 850 re-entry line.
AMD:NASDAQAMDWatchHeld-below-518 test failed; closed 10.9% under 50-day average.

Tenbagger radar

  • BlackSky (BKSY:NYSE): kept at 7.9x on the briefing's assumptions. The rise reflects a lower share price, not new evidence. Robinhood distribution is new.
  • UBTech (9880:HKEX): kept at 6.1x. Runway is under two years, and a new intraday low is a weakening factor.
  • RoboSense (2498:HKEX): kept at 9.6x, the highest in the pool. Price keeps making new lows.
  • Firefly Aerospace (FLY:NASDAQ): kept at 6.3x. Two brokers cut targets before earnings. The 10 November gross margin of at least 15% is a hard test.
  • Beam Therapeutics (BEAM:NASDAQ): kept at 7.8x. The ASH oral slot gives the next data point a date.
  • Intuitive Machines (LUNR:NASDAQ): added at 5.5x on the larger market-cap basis (7.9x on the smaller). Safety margin is thin. Nothing left the pool.

Risks to watch

  • Policy: the Texas legislature meets in January, and ERCOT rules on large-load pauses in December. Vistra reports 6 November and gives the first power-side read.
  • Earnings: BlackSky, Hua Hong, BeiGene and Lumentum on 5 November. Rocket Lab and AST SpaceMobile 9 November, Firefly 10 November, AMAT and SMIC 12 November, Nvidia 17 November.
  • Pricing and discipline: TSM and Regeneron sit close to their stops, and the Vertiv stop is 187.28.
  • Biotech dates: Vertex povetacicept PDUFA on 30 November; FDA gene-editing draft comment period closes 27 November.

AI-written summary of a Chinese-language briefing that is itself AI-assisted. For discussion and research only; not investment advice.